Department of Clinical Immunology, Institute of Laboratory Medicine and IdISSC, Hospital Clínico San Carlos, Madrid, Spain.
Department of Immunology, Ophthalmology and ENT, School of Medicine, Complutense University, Madrid, Spain.
J Clin Immunol. 2024 Oct 23;45(1):32. doi: 10.1007/s10875-024-01818-2.
Distinguishing between primary (PID) and secondary (SID) immunodeficiencies, particularly in relation to hematological B-cell lymphoproliferative disorders (B-CLPD), poses a major clinical challenge. We aimed to analyze and define the clinical and laboratory variables in SID patients associated with B-CLPD, identifying overlaps with late-onset PIDs, which could potentially improve diagnostic precision and prognostic assessment. We studied 37 clinical/laboratory variables in 151 SID patients with B-CLPD. Patients were classified as "Suspected PID Group" when having recurrent-severe infections prior to the B-CLPD and/or hypogammaglobulinemia according to key ESID criteria for PID. Bivariate association analyses showed significant statistical differences between "Suspected PID"- and "SID"-groups in 10 out of 37 variables analyzed, with "Suspected PID" showing higher frequencies of childhood recurrent-severe infections, family history of B-CLPD, significantly lower serum Free Light Chain (sFLC), immunoglobulin concentrations, lower total leukocyte, and switch-memory B-cell counts at baseline. Rpart machine learning algorithm was performed to potentially create a model to differentiate both groups. The model developed a decision tree with two major variables in order of relevance: sum κ + λ and history of severe-recurrent infections in childhood, with high sensitivity 89.5%, specificity 100%, and accuracy 91.8% for PID prediction. Identifying significant clinical and immunological variables can aid in the difficult task of recognizing late-onset PIDs among SID patients, emphasizing the value of a comprehensive immunological evaluation. The differences between "Suspected PID" and SID groups, highlight the need of early, tailored diagnostic and treatment strategies for personalized patient management and follow up.
区分原发性(PID)和继发性(SID)免疫缺陷,特别是与血液学 B 细胞淋巴增殖性疾病(B-CLPD)相关,是一项重大的临床挑战。我们旨在分析和定义 SID 患者与 B-CLPD 相关的临床和实验室变量,确定与迟发性 PID 的重叠,这可能有助于提高诊断精度和预后评估。我们研究了 151 例 SID 患者伴 B-CLPD 的 37 项临床/实验室变量。当患者在 B-CLPD 之前有复发性严重感染和/或根据 PID 的关键 ESID 标准存在低丙种球蛋白血症时,将其归类为“疑似 PID 组”。二变量关联分析显示,在分析的 37 个变量中有 10 个在“疑似 PID”和“SID”组之间存在显著的统计学差异,“疑似 PID”组的儿童复发性严重感染、B-CLPD 家族史、显著较低的血清游离轻链(sFLC)、免疫球蛋白浓度、较低的总白细胞和初始记忆 B 细胞计数的频率更高。Rpart 机器学习算法用于潜在地创建一个模型来区分这两组。该模型开发了一个决策树,其中两个主要变量按相关性排序:总和 κ + λ 和儿童期严重复发性感染史,对 PID 的预测具有高敏感性 89.5%、特异性 100%和准确性 91.8%。确定重要的临床和免疫学变量可以帮助识别 SID 患者中的迟发性 PID,强调全面免疫评估的价值。“疑似 PID”和 SID 组之间的差异突出了为个体化患者管理和随访制定早期、定制的诊断和治疗策略的必要性。